Navigation Links
Instanyl sets new standard in management of breakthrough cancer pain
Date:9/11/2009

Lisbon, Portugal 11 September, 2009 New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer. The study concludes that pain relief was significantly greater for Instanyl compared to OTFC at all time points:

  • 25% of episodes showed meaningful pain relief already at 5 minutes after treatment with Instanyl, as compared to 7% with OTFC. (p<0.001) (1)

  • 51% of the Instanyl treated patients had a meaningful pain relief at 10 minutes, as compared to 24% with OTFC. (p<0.001) (1)

"These data confirm the superiority of the intranasal drug administration over OTFC. Rapid pain relief is essential for the management of breakthrough cancer pain and with evidence of onset of pain relief as early as 5 minutes, Instanyl offers patients a much more effective pain control than OTFC," said Professor Sebastiano Mercadante, principal investigator of the comparative study and Director of the Anesthesia and Intensive Care and Pain Relief and Palliative Care Units at La Maddalena Cancer Center, Palermo, Italy.

The study also showed that patients found Instanyl significantly easier to administer than OTFC, with 90% of patients finding Instanyl 'easy' or 'very easy' to use, compared to 40% of OTFC patients (2). Instanyl is the first intranasal treatment for breakthrough cancer pain to be licensed and the study showed that 77% of patients preferred Instanyl to OTFC (2).

"With a preference for Instanyl more than three-fold higher compared to OTFC the study confirms that with Instanyl patients now have a treatment that they feel better matches their need," s
'/>"/>

Contact: Mette Thorn Srensen
mts@cohnwolfe.dk
454-138-4300
Cohn & Wolfe, Copenhagen
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
2. GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with GLN Sunrise Date
3. Quality of Medicines Advanced by Agreement Between USP, Mexican Standards Body
4. Standard & Poor's Upgrades Wellmont Outlook
5. New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures
6. Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device
7. NMB's New Series of Standard Hybrid Stepper Motors Now Available
8. Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards
9. CAS REGISTRY(SM), the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
10. Sedationfacts.org Enhances State-Specific Site Content, Making Regional Sedation Administration Standards and Regulations Quick and Easy to Find and Use
11. Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published ... Reconstructive Surgery Global Open Journal that discusses the future of 3-D printing technology as ... the future, customized implants, prosthetics, and other 3-D printed tools could be used to ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... the Joint Replacement Surgery Program at Monmouth, was one of the first doctors ... decade, the results of this new approach have been impressive: faster recovery, decreased ...
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical and ... orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , Dr. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet ... down costs? , In a commentary for The American Journal of Managed ... of “clinical efficacy,” which would bind parties together in agreements to intervene at ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... Ill. -- A growing number of health research programs ... groups help recruit study participants, obtain informed consent, collect ... But existing programs that educate researchers, community groups ... meet the needs of all groups that have a ...
... 2012 A new study finds differences in screening ... in colorectal cancer incidence and nearly 20 percent of ... stage-specific survival, which likely reflect differences in treatment account ... cancer mortality rates. The study, appearing early online in ...
... WEDNESDAY, May 2 (HealthDay News) -- Finding out who the ... emergence of a simple blood test for women that can ... The paternity screening, developed at a private biotech company in ... are done later in the pregnancy, its developer says. ...
... increases the life expectancy of men by 6.2 years and ... Copenhagen City Heart study presented at the EuroPRevent2012 meeting. ... Peter Schnohr told delegates that the study,s most recent analysis ... of jogging per week at a "slow or average" ...
... is currently the leading cause of pregnancy-related deaths during ... publication in The Endocrine Society,s Journal of Clinical ... adrenomedullin (ADM) may help predict this condition. TEP ... the fallopian tubes instead of in the uterus. In ...
... women aged 40-49 diagnosed with breast cancer on screening mammography report ... conducted at Elizabeth Wende Breast Care, LLC in Rochester, NY of ... out of 373 cancers (61%) were found in women, aged 40-49 ... the 228 patients did have a prior personal history of breast ...
Cached Medicine News:Health News:Better ethics education needed in community-based research 2Health News:Study says screening accounts for much of black/white disparity in colorectal cancer 2Health News:Who's the Dad? First-Trimester Blood Test May Tell 2Health News:Who's the Dad? First-Trimester Blood Test May Tell 3Health News:Regular jogging shows dramatic increase in life expectancy 2Health News:Regular jogging shows dramatic increase in life expectancy 3Health News:Hormone may help predict tubal ectopic pregnancy 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: